These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 32835256)

  • 1. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study.
    De Luca G; Cavalli G; Campochiaro C; Della-Torre E; Angelillo P; Tomelleri A; Boffini N; Tentori S; Mette F; Farina N; Rovere-Querini P; Ruggeri A; D'Aliberti T; Scarpellini P; Landoni G; De Cobelli F; Paolini JF; Zangrillo A; Tresoldi M; Trapnell BC; Ciceri F; Dagna L
    Lancet Rheumatol; 2020 Aug; 2(8):e465-e473. PubMed ID: 32835256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial.
    Cremer PC; Abbate A; Hudock K; McWilliams C; Mehta J; Chang SY; Sheng CC; Van Tassell B; Bonaventura A; Vecchié A; Carey B; Wang Q; Wolski KE; Rajendram P; Duggal A; Wang TS; Paolini JF; Trapnell BC;
    Lancet Rheumatol; 2021 Jun; 3(6):e410-e418. PubMed ID: 33754144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.
    Cavalli G; De Luca G; Campochiaro C; Della-Torre E; Ripa M; Canetti D; Oltolini C; Castiglioni B; Tassan Din C; Boffini N; Tomelleri A; Farina N; Ruggeri A; Rovere-Querini P; Di Lucca G; Martinenghi S; Scotti R; Tresoldi M; Ciceri F; Landoni G; Zangrillo A; Scarpellini P; Dagna L
    Lancet Rheumatol; 2020 Jun; 2(6):e325-e331. PubMed ID: 32501454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Mavrilimumab in Viral Infections Including SARS-CoV-2 Infection - A Brief Review.
    Bhatt K; Garimella R; Taugir R; Mehta I; Jamal M; Vijayan R; Offor R; Nwankwo K; Arif U; Waheed K; Kumari P; Lathiya M; Michel G; Pandya N; Halpern J; Nasir H; Sanchez-Gonzalez MA
    Infect Chemother; 2021 Mar; 53(1):1-12. PubMed ID: 34409778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis.
    Guo X; Higgs BW; Bay-Jensen AC; Wu Y; Karsdal MA; Kuziora M; Godwood A; Close D; Ryan PC; Roskos LK; White WI
    Rheumatology (Oxford); 2018 Jan; 57(1):175-184. PubMed ID: 29069507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a Phase IIa study.
    Takeuchi T; Tanaka Y; Close D; Godwood A; Wu CY; Saurigny D
    Mod Rheumatol; 2015 Jan; 25(1):21-30. PubMed ID: 24720551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study.
    Burmester GR; Feist E; Sleeman MA; Wang B; White B; Magrini F
    Ann Rheum Dis; 2011 Sep; 70(9):1542-9. PubMed ID: 21613310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.
    Burmester GR; McInnes IB; Kremer JM; Miranda P; Vencovský J; Godwood A; Albulescu M; Michaels MA; Guo X; Close D; Weinblatt M
    Arthritis Rheumatol; 2018 May; 70(5):679-689. PubMed ID: 29361199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): a prospective, multicentre cohort study.
    Estenssoro E; Loudet CI; Ríos FG; Kanoore Edul VS; Plotnikow G; Andrian M; Romero I; Piezny D; Bezzi M; Mandich V; Groer C; Torres S; Orlandi C; Rubatto Birri PN; Valenti MF; Cunto E; Sáenz MG; Tiribelli N; Aphalo V; Reina R; Dubin A;
    Lancet Respir Med; 2021 Sep; 9(9):989-998. PubMed ID: 34224674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study.
    Hsu TY; D'Silva KM; Patel NJ; Wang J; Mueller AA; Fu X; Prisco L; Martin L; Vanni KMM; Zaccardelli A; Cook C; Choi HK; Zhang Y; Gravallese EM; Wallace ZS; Sparks JA
    Lancet Rheumatol; 2021 Sep; 3(9):e638-e647. PubMed ID: 34095857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation.
    Potere N; Di Nisio M; Rizzo G; La Vella M; Polilli E; Agostinone A; Spacone A; Di Carlo S; Costantini A; Abbate A; Porreca E; Parruti G
    Int J Infect Dis; 2020 Nov; 100():421-424. PubMed ID: 32768701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
    Grasselli G; Zangrillo A; Zanella A; Antonelli M; Cabrini L; Castelli A; Cereda D; Coluccello A; Foti G; Fumagalli R; Iotti G; Latronico N; Lorini L; Merler S; Natalini G; Piatti A; Ranieri MV; Scandroglio AM; Storti E; Cecconi M; Pesenti A;
    JAMA; 2020 Apr; 323(16):1574-1581. PubMed ID: 32250385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study.
    Cavalli G; Larcher A; Tomelleri A; Campochiaro C; Della-Torre E; De Luca G; Farina N; Boffini N; Ruggeri A; Poli A; Scarpellini P; Rovere-Querini P; Tresoldi M; Salonia A; Montorsi F; Landoni G; Castagna A; Ciceri F; Zangrillo A; Dagna L
    Lancet Rheumatol; 2021 Apr; 3(4):e253-e261. PubMed ID: 33655218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
    Weinblatt ME; McInnes IB; Kremer JM; Miranda P; Vencovsky J; Guo X; White WI; Ryan PC; Godwood A; Albulescu M; Close D; Burmester GR
    Arthritis Rheumatol; 2018 Jan; 70(1):49-59. PubMed ID: 28941039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial.
    Bosteels C; Maes B; Van Damme K; De Leeuw E; Declercq J; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):491. PubMed ID: 32503663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab.
    Cook AD; Hamilton JA
    Ther Adv Musculoskelet Dis; 2018 Feb; 10(2):29-38. PubMed ID: 29387176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: relevance for human safety.
    Ryan PC; Sleeman MA; Rebelatto M; Wang B; Lu H; Chen X; Wu CY; Hinrichs MJ; Roskos L; Towers H; McKeever K; Dixit R
    Toxicol Appl Pharmacol; 2014 Sep; 279(2):230-9. PubMed ID: 24937321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study.
    Karagiannidis C; Mostert C; Hentschker C; Voshaar T; Malzahn J; Schillinger G; Klauber J; Janssens U; Marx G; Weber-Carstens S; Kluge S; Pfeifer M; Grabenhenrich L; Welte T; Busse R
    Lancet Respir Med; 2020 Sep; 8(9):853-862. PubMed ID: 32735842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.